M.C. Vekemans Archives - Page 4 of 9

P16 Preleukemic phase of chronic myeloid leukemia presenting with an isolated peripheral basocytosis

BJH - 2018, issue Abstract Book BHS, february 2018

F. Dall’Armellina , Y. Berners , L. Maindiaux , A. Capes , J-P. Defour PhD, P. Saussoy MD, PhD, V. Havelange MD, PhD, M.C. Vekemans MD

P29 Breast implants: a rare cause of anaplastic large T-cell lymphoma

BJH - 2018, issue Abstract Book BHS, february 2018

S. Bailly MD, Y. Breners , S. Amat , L. Maindiaux , F. Dall’Armellina , C. Galant , A. Camboni MD, PhD, M. Coyette , E. Van den Neste MD, PhD, M.C. Vekemans MD

P46 About a case of allogenic hematopoietic stem cell transplant-associated thrombotic microangiopathy

BJH - 2018, issue Abstract Book BHS, february 2018

Y. Berners , A. Capes , F. Dall’Armellina , L. Maindiaux , J. Morelle MD, PhD, K. Claes BM, PhD, C. Lambert MD, PhD, X. Poiré MD, PhD, M.C. Vekemans MD

P52 Pancytopenia induced by visceral leishmaniasis in a patient with relapsed multiple myeloma

BJH - 2018, issue Abstract Book BHS, february 2018

S. Amat , M.C. Vekemans MD, J-P. Defour PhD, J.C. Yombi , I. Stoian , S. Bailly MD

P60 Monoclonal gammopathy of clinical significance: an IgG-lambda monoclonal gammopathy associated with renal failure, lung disease and cutis laxa

BJH - 2018, issue Abstract Book BHS, february 2018

L. Maindiaux , F. Dall’Armellina , Y. Berners , A. Capes , V. Gillion , J. Lelotte , L. Marot , J-P. Defour PhD, M.C. Vekemans MD

P61 Drug induced neutropenia with myelodysplasia with blast excess

BJH - 2018, issue Abstract Book BHS, february 2018

A. Capes , F. Dall’Armellina , Y. Berners , L. Maindiaux , T. Connerotte MD, A. Camboni MD, PhD, P. Saussoy MD, PhD, J-P. Defour PhD, X. Poiré MD, PhD, N. Straetmans MD, PhD, M.C. Vekemans MD

Update on therapy of relapsed and refractory multiple myeloma

BJH - volume 8, issue 2, march 2017

M.C. Vekemans MD, K. Beel MD, PhD, J. Caers MD, PhD, N. Meuleman MD, PhD, G. Bries MD, PhD, H. Demuynck MD, B. De Prijck MD, H. De Samblanx MD, A. Deweweire MD, K. Fostier MD, A. Kentos MD, PhD, P. Mineur MD, M. Vaes MD, I. Vande Broek MD, PhD, A. Vande Velde MD, J. Van Droogenbroeck MD, P. Vlummens MD, K.L. Wu MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD, On behalf of the Multiple Myeloma Study Group of the Belgian Haematology Society (BHS)

SUMMARY

The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity. However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.

(BELG J HEMATOL 2017;8(2):53–65)